NVO240913C129000
- 4.09
- 0.000.00%
Novo-Nordisk A/S Newsroom
Evaluating Novo Nordisk: Insights From 8 Financial Analysts
Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
Terns Stock Jumps as Weight Loss Drug Succeeds in Early Trial
Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk
Is Novo Nordisk A/S (NVO) A Good Biotech Stock to Buy?
Why Big Pharma Is Betting on Telehealth Strategies
Novo Nordisk to Present New Data From Key Diabetes and Obesity Trials at the 60th Annual Meeting of the European Association for the Study of Diabetes
Who Can Use the New Obesity Drugs? Nearly Half of Adults Under 65 Are Eligible. -- Barrons.com
Eli Lilly Makes Strides on Weekly Insulin Shot as Novo Nordisk Stumbles
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
Battle Over Compounded Weight-Loss Medications - Sustainability and Regulation
Novo Nordisk Unusual Options Activity
European Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading
Novo Nordisk's 2H Catalysts Could Redefine Obesity Market -- Market Talk
Eli Lilly's Weekly Insulin Intensifies Race With Novo Nordisk
UK Regulators Find No Link Between Certain GLP-1 Drugs, Suicidal Thoughts
BofA's Global Contenders and Defenders List
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
MHRA Finds No Evidence Supporting Link Between GLP-1 Receptor Agonists And Suicidal Thoughts Or Actions; Will Continue Monitoring Risk Of Severe Psychiatric Reactions
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity